Physician profile
Michael Wayne Chan
NPI 1003841834
$4,965.05
in general payments reported to CMS, 2019-2025
24 companies · $547 in 2025
The $547 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $774 · 2020: $412 · 2021: $785 · 2022: $852 · 2023: $695 · 2024: $899 · 2025: $547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,141.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $714.47 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $479.04 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $453.56 | 2019-2024 | Farxiga, Brilinta |
| E.R. Squibb & Sons, L.L.C. | $322.78 | 2019-2024 | Eliquis, Camzyos |
| Medtronic, INC. | $313.91 | 2022-2024 | Selectsecure |
| Abbott Laboratories | $308.28 | 2020-2025 | Tendril |
| Amgen INC. | $299.50 | 2019-2025 | Repatha, Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $296.05 | 2021-2025 | |
| Pfizer INC. | $289.63 | 2019-2025 | |
| Asahi Intecc Co., LTD. | $265.13 | 2024 | Peripheral Vascular |
| Novartis Pharmaceuticals Corporation | $238.80 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $222.29 | 2019-2024 | Lifevest |
| Merck Sharp & Dohme LLC | $212.23 | 2022-2025 | Verquvo |
| Abiomed | $129.83 | 2023 | Impella |
| Esperion Therapeutics, INC. | $128.27 | 2021-2025 | Nexletol |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $64.46 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $50.05 | 2019 | |
| Vifor Pharma, INC. | $41.77 | 2019 | |
| Boston Scientific Corporation | $31.62 | 2025 | Accolade Sr |
| Gilead Sciences, INC. | $24.65 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $24.23 | 2023 | Inpefa |
| Stryker Corporation | $22.18 | 2025 | Inthrill Thrombectomy Catheter |
| Sanofi-Aventis U.S. LLC | $21.39 | 2019 | |
| Atricure, INC. | $10.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.